Mangoceuticals, Inc. \ a company focused on developing, marketing, and selling a variety of men’s health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is pleased to announce that it has received a Certificate of Grant and recordal of patent under section 43 of the Patents Act in respect of patent application no. 202117034253 with the Government of India, originally applied for by Intramont Technologies, Inc. (“Intramont”).

The duration of the patent granted in India is twenty (20) years from the effective filing date of the application, or until March 16, 2040.

This significant milestone follows MangoRx’s recent acquisition of the comprehensive global patent portfolio from Intramont Technologies. The Certificate of Grant covers the proprietary formulation and application methods designed to combat a wide range of infections, including common colds, respiratory diseases, and orally transmitted infections such as human papillomavirus (HPV). The US patent (Patent 11,517,523) was initially applied for by Intramont and subsequently acquired by MangoRx on April 24, 2024, further expanding the global protection for its groundbreaking preventive care technology.

Jacob Cohen, Co-Founder and CEO of MangoRx, expressed his enthusiasm about this achievement: “Receiving this Certificate of Grant in India is a critical step in our global strategy to protect and commercialize our innovative preventive care technology. It underscores our commitment to expanding our reach and providing advanced preventive care solutions to a broader audience. This patent not only fortifies our intellectual property but also paves the way for introducing our cutting-edge products to the market in India.”

The patented technology is designed to prevent illnesses acquired through the oral cavity and pharynx using an orally available solution, such as toothpaste, oral dissolvable tablets (ODT), lozenges, or mouthwash. The unique formulation features GALALCOOL^®️, zinc protoporphyrin IX, and select tannins, which work synergistically to inhibit various pathogens, offering comprehensive protection against oral and respiratory infections.

In parallel with this patent grant, MangoRx and Intramont have initiated clinical trials for this technology, collaborating with Vipragen Biosciences in India. These trials aim to demonstrate the efficacy of the formulation in preventing respiratory illnesses, with results expected later this quarter. The study focuses on evaluating the technology’s prophylactic performance against select viral strains, including H1N1, with the potential to expand into further trials involving the H5N1 strain to address concerns related to avian influenza outbreaks.

This expansion aligns with MangoRx’s mission to enhance well-being through innovative health solutions. The Certificate of Grant in India joins an already robust portfolio of U.S. and international patents, including its recent patent grants in Australia and Japan, reinforcing MangoRx’s position of becoming a leader in the preventive health sector.